Jonathan Cohen
Founder, CEO
Jonathan Cohen is the founder, president, and CEO of 20/20 GeneSystems. Under Mr. Cohen’s leadership, 20/20 has brought in approximately $7.5 million in grant funding and launched two successful products, a bio-detection kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the early detection of lung cancer. He is the co-inventor of an AI approach for improving tumor biomarker accuracy that is covered in a pending PCT International Patent Application.
Michael S. Lebowitz, PhD
Chief Scientific Officer
Dr. Lebowitz has more than 18 years of experience in biomedical research within the biotech industry having previously served as Vice President of Research at Ariadne Diagnostics, LLC. He has been directly involved in the commercial launch of six cancer diagnostic tests and the research leading up to a pharmaceutical IND approval. Dr. Lebowitz holds a Ph.D. from the Johns Hopkins University School of Medicine in Biochemistry, Cellular, and Molecular Biology where he subsequently completed a three-year fellowship in immunology in the Department of Pathology, Division of Immunopathology.
Jiming Zhou
COO
Dr. Zhou graduated from Sichuan University (China) and served as an Associate Professor before moving to the US, conducting academic research at University of Iowa, focusing on lung cancer and other disorders. Dr. Zhou then joined industrial R&D, led a joint pharmaceutical project total milestones of $330 million. From 2009, Dr. Zhou directed 2 independent clinical labs and co-funded 2 companies, worked with many large US and Chinese public and private healthcare institutes in multiple projects. Dr. Zhou published 20+ peer-reviewed manuscripts and owns several patents.
